State of the art molecular diagnostics and therapy of chronic lymphocytic leukaemia in the era of new targeted therapies
Chronic lymphoid leukaemia (CLL) has a heterogeneous clinical course depending on many clinical and molecular prognostic markers, which play an important role in the selection of the best treatment option. So far, TP53 disruption is the key prognostic and predictive factor assisting treatment decisions, especially in the era of novel therapies. Asymptomatic patients in early stages of the disease will still benefit from watchful waiting. In the frontline setting, chemoimmunotherapy is still the standard care in the majority of standard risk CLL patients. New classes of drugs like kinase inhibitors and BCL-2 inhibitors (ibrutinib, idelalisib and venetoclax) are the treatment of choice in CLL patients with relapsed/refractory disease, with the exception of high risk disease, where the optimal treatment is frontline ibrutinib monotherapy. In the near future, integrating next generation sequencing into the routine diagnostics would help the development of individual CLL patient management and to choose an optimal treatment strategy. Orv Hetil. 2017; 158(41): 1620-1629.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:158 |
|---|---|
| Enthalten in: |
Orvosi hetilap - 158(2017), 41 vom: 01. Okt., Seite 1620-1629 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
A krónikus lymphocytás leukaemia korszerű molekuláris diagnosztikája és kezelése az új célzott terápiák korszakában |
|---|
| Beteiligte Personen: |
Gurbity Pálfi, Tímea [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.12.2017 Date Revised 14.12.2017 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1556/650.2017.30870 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM276941675 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM276941675 | ||
| 003 | DE-627 | ||
| 005 | 20231225013112.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||hun c | ||
| 024 | 7 | |a 10.1556/650.2017.30870 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0923.xml |
| 035 | |a (DE-627)NLM276941675 | ||
| 035 | |a (NLM)29025288 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Gurbity Pálfi, Tímea |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a State of the art molecular diagnostics and therapy of chronic lymphocytic leukaemia in the era of new targeted therapies |
| 246 | 3 | 3 | |a A krónikus lymphocytás leukaemia korszerű molekuláris diagnosztikája és kezelése az új célzott terápiák korszakában |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.12.2017 | ||
| 500 | |a Date Revised 14.12.2017 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Chronic lymphoid leukaemia (CLL) has a heterogeneous clinical course depending on many clinical and molecular prognostic markers, which play an important role in the selection of the best treatment option. So far, TP53 disruption is the key prognostic and predictive factor assisting treatment decisions, especially in the era of novel therapies. Asymptomatic patients in early stages of the disease will still benefit from watchful waiting. In the frontline setting, chemoimmunotherapy is still the standard care in the majority of standard risk CLL patients. New classes of drugs like kinase inhibitors and BCL-2 inhibitors (ibrutinib, idelalisib and venetoclax) are the treatment of choice in CLL patients with relapsed/refractory disease, with the exception of high risk disease, where the optimal treatment is frontline ibrutinib monotherapy. In the near future, integrating next generation sequencing into the routine diagnostics would help the development of individual CLL patient management and to choose an optimal treatment strategy. Orv Hetil. 2017; 158(41): 1620-1629 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a TP53 disruption | |
| 650 | 4 | |a TP53-defektus | |
| 650 | 4 | |a chemoimmunotherapy | |
| 650 | 4 | |a chronic lymphocytic leukaemia | |
| 650 | 4 | |a célzott kezelés | |
| 650 | 4 | |a ibrutinib | |
| 650 | 4 | |a kemo-immuno terápia | |
| 650 | 4 | |a krónikus lymphocytás leukaemia | |
| 650 | 4 | |a prognostic marker | |
| 650 | 4 | |a prognosztikai marker | |
| 650 | 4 | |a targeted therapy | |
| 650 | 4 | |a venetoclax | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Fésüs, Viktória |e verfasserin |4 aut | |
| 700 | 1 | |a Bödör, Csaba |e verfasserin |4 aut | |
| 700 | 1 | |a Borbényi, Zita |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Orvosi hetilap |d 1949 |g 158(2017), 41 vom: 01. Okt., Seite 1620-1629 |w (DE-627)NLM000021601 |x 1788-6120 |7 nnns |
| 773 | 1 | 8 | |g volume:158 |g year:2017 |g number:41 |g day:01 |g month:10 |g pages:1620-1629 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1556/650.2017.30870 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 158 |j 2017 |e 41 |b 01 |c 10 |h 1620-1629 | ||